A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 110 sites in 2 countries. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-06.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 2nd largest by enrollment, is one of 5 that started in 2020, is one of 14 in phase 3, and was the 5th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United States
Ages 2 mo–15 mo · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 42 Days to 98 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 5 started in 2020.
This study's enrollment of 1,997 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 668 across the 19 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 4 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 7th largest by enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2020, is one of 33 in phase 3, and was the 50th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
1 of the studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pneumococcal conjugate vaccine
Biological: 20-valent pneumococcal conjugate vaccine
Pneumococcal conjugate vaccine
Biological: 13-valent pneumococcal conjugate vaccine
20-valent pneumococcal conjugate vaccine
13-valent pneumococcal conjugate vaccine
Percentage of Participants With Local Reactions Within 7 Days After Dose 1
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).
Time frame: Within 7 days after Dose 1
Percentage of Participants With Local Reaction Within 7 Days After Dose 2
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).
Time frame: Within 7 Days After Dose 2
Percentage of Participants With Local Reactions Within 7 Days After Dose 3
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).
Time frame: Within 7 days after Dose 3
Percentage of Participants With Local Reactions Within 7 Days After Dose 4
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.
Time frame: Within 7 days after Dose 4
Percentage of Participants With Systemic Events Within 7 Days After Dose 1
Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature greater than or equal to (\>=) 38.0 degrees Celsius (C) and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
Time frame: Within 7 days after Dose 1
Percentage of Participants With Systemic Events Within 7 Days After Dose 2
Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>= 38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
Time frame: Within 7 days after Dose 2
Percentage of Participants With Systemic Events Within 7 Days After Dose 3
Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>= 38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
Time frame: Within 7 days after Dose 3
Percentage of Participants With Systemic Events Within 7 Days After Dose 4
Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>= 38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
Time frame: Within 7 days after Dose 4
Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3
An AE was any untoward medical occurrence in a participants, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events.
Time frame: From Dose 1 to 1 Month after Dose 3
Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 4
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events.
Time frame: From Dose 4 to 1 month after Dose 4
Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 6 Months Following Dose 4
A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalisation or prolongation of existing hospitalisation; was life-threatening; resulted in persistent or significant disability/ incapacity; congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.
Time frame: From Dose 1 to 6 months following Dose 4
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 6 Months Following Dose 4
An NDCMC was defined as a significant disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.
Time frame: From Dose 1 to 6 months following Dose 4
Percentage of Participants With Predefined Serotype-specific Immunoglobulin G (IgG) Concentrations 1 Month After Dose 3
Pre-specified levels of serotypes were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per mL (mcg/mL), for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.
Time frame: 1 month after Dose 3
Serotype-specific IgG Geometric Mean Concentration (GMCs) and Geometric Mean Ratios (GMRs) at 1 Month After Dose 4
Concentrations of anticapsular IgG for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in all participants at 1 month after Dose 4 using the Luminex assay. Results were expressed as IgG concentrations. GMCs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. Assay result below LLOQ was set to 0.5\*LLOQ. Geometric mean ratios (GMRs) were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CIs (based on Student's t distribution).
Time frame: From Dose 1 to 6 months following Dose 4
Percentage of Participants With Prespecified Antibody Levels to Specific Concomitant Vaccine Antigens 1 Month After Dose 3
Concentration of antibody to diphtheria toxoid (predefined level ≥0.1 IU/mL), tetanus toxoid (predefined level ≥0.1 IU/mL), IgG antibodies to pertussis antigens (pertussis toxin, filamentous hemagglutinin and pertactin, each with the predefined level as the 5th percentile observed in the 13vPnC group), hepatitis B antibody (in milli-international units per mL \[mIU/mL\]) (predefined level ≥10 mIU/mL), neutralizing antibody (NA) titers to poliovirus types 1, 2, and 3 (predefined level NA titer ≥1:8), Haemophilus influenzae type b (Hib) (≥0.15 μg/mL) were determined on subsets of sera collected at the immunogenicity time point 1 month after Dose 3. The antibody levels were measured by a validated multiplex Luminex immunoassay. The concomitant immune responses were measured on random subsets.
Time frame: 1 month after Dose 3
Serotype-specific IgG GMCs and GMRs at 1 Month After Dose 3
Pneumococcal IgG antibody against each of the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F) was measured using direct binding Luminex assay. Results were expressed as IgG concentrations. GMCs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. Assay result below LLOQ were set to 0.5\*LLOQ.GMRs were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CI (based on Student's t distribution). Assay result below LLOQ were set to 0.5\*LLOQ.GMRs were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CI (based on Student's t distribution).
Time frame: 1 month after Dose 3
Percentage of Participants With Predefined IgG Concentrations 1 Month After Dose 4
Pre-specified levels of serotypes were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per mL (mcg/mL), for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.
Time frame: 1 month after Dose 4
Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at 1 Month After Dose 3
OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomized subsets of participants at 1 month after Dose 3. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. OPA titers were determined in randomized subsets of participants at 1 month after Dose 3.
Time frame: 1 month after Dose 3
Serotype-specific OPA GMTs at 1 Month After Dose 4
OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomized subsets of participants at 1 month after Dose 4. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. OPA titers were determined in randomized subsets of participants at 1 month after Dose 4.
Time frame: 1 month after Dose 4
Serotype-specific IgG Geometric Mean Fold Rise (GMFRs) From 1 Month After Dose 3 to Before Dose 4
GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. The GMFR from 1 month after Dose 3 to before Dose 4 were reported from Dose 3 evaluable immunogenicity participant.
Time frame: 1 month after Dose 3 to before Dose 4
Serotype-specific IgG GMFRs From 1 Month Before to 1 Month After Dose 4
GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. The GMFR from 1 month before Dose 4 to 1 month after Dose 4 were reported from Dose 4 evaluable immunogenicity participants.
Time frame: From 1 month before to 1 month after Dose 4
Serotype-specific IgG GMFRs From 1 Month After Dose 3 to 1 Month After Dose 4
GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. The GMFR from 1 month after Dose 3 to 1 month after Dose 4 were reported from participants in both Dose 3 and Dose 4 evaluable immunogenicity populations.
Time frame: from 1 month after Dose 3 to 1 month after Dose 4
Percentage of Participants With Alternative Prespecified Hib Antibody Level 1 Month After Dose 3
Antibody concentration to the Hib vaccine antigens were determined on sera collected from a randomly selected subset of participants with sufficient sera volumes. Percentage of participants with alternative prespecified Hib antibody (≥1.0 μg/mL) were reported from Dose 3 evaluable immunogenicity participants.
Time frame: 1 month after Dose 3
Geometric Mean Ratios (GMRs) of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Measles) 1 Month After Dose 4
Antibody concentrations to concomitant vaccine antigen (measles) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.
Time frame: 1 month after Dose 4
GMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Mumps) 1 Month After Dose 4
Antibody concentrations to concomitant vaccine antigen (mumps) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.
Time frame: 1 month after Dose 4
GMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigens (Rubella) 1 Month After Dose 4
Antibody concentrations to concomitant vaccine antigen (rubella) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.
Time frame: 1 month after Dose 4
GMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Varicella) 1 Month After Dose 4
Antibody concentrations to concomitant vaccine antigen (varicella) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.
Time frame: 1 month after Dose 4
| Milestone | 20vPnC | 13vPnC |
|---|---|---|
| Started | 1001 | 987 |
| Completed | 821 | 799 |
| Not completed | 180 | 188 |
| Withdrew: Adverse event, not serious | 1 | 2 |
| Withdrew: Other | 1 | 0 |
| Withdrew: Withdrawal by parent/guardian | 50 | 54 |
| Withdrew: No longer meets eligibility criteria | 50 | 44 |
| Withdrew: Protocol violation | 29 | 23 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Lost to follow-up | 48 | 63 |
| Withdrew: Adverse event, non-fatal | 1 | 1 |
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Redness: Any | 25.5 (22.8 to 28.3) | 24.6 (22.0 to 27.5) |
| Redness: Mild | 21.5 (18.9 to 24.1) | 22.3 (19.7 to 25.0) |
| Redness: Moderate | 4.0 (2.9 to 5.4) | 2.4 (1.5 to 3.5) |
| Redness: Severe | 0 (0.0 to 0.4) | 0 (0.0 to 0.4) |
| Swelling: Any | 16.4 (14.2 to 18.9) | 18.8 (16.4 to 21.4) |
| Swelling: Mild | 11.5 (9.6 to 13.6) | 14.7 (12.5 to 17.1) |
| Swelling: Moderate | 4.8 (3.6 to 6.4) | 4.1 (2.9 to 5.6) |
| Swelling: Severe | 0.1 (0.0 to 0.6) | 0 (0.0 to 0.4) |
| Pain at the injection site: Any | 49.1 (46.0 to 52.3) | 45.3 (42.1 to 48.5) |
| Pain at the injection site: Mild | 30.6 (27.8 to 33.6) | 30.4 (27.5 to 33.4) |
| Pain at the injection site: Moderate | 18.4 (16.1 to 21.0) | 14.9 (12.7 to 17.3) |
| Pain at the injection site: Severe | 0.1 (0.0 to 0.6) | 0 (0.0 to 0.4) |
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Redness: Any | 23.2 (20.5 to 26.0) | 26.4 (23.6 to 29.4) |
| Redness: Mild | 21.2 (18.6 to 23.9) | 23.1 (20.4 to 25.9) |
| Redness: Moderate | 2.0 (1.2 to 3.1) | 3.4 (2.3 to 4.7) |
| Redness: Severe | 0 (0.0 to 0.4) | 0 (0.0 to 0.4) |
| Swelling: Any | 15.5 (13.3 to 18.0) | 17.3 (14.9 to 19.9) |
| Swelling: Mild | 11.5 (9.5 to 13.7) | 13.5 (11.4 to 15.9) |
| Swelling: Moderate | 4.0 (2.9 to 5.5) | 3.8 (2.7 to 5.2) |
| Swelling: Severe | 0 (0.0 to 0.4) | 0 (0.0 to 0.4) |
| Pain at the injection site: Any | 44.0 (40.8 to 47.3) | 41.7 (38.5 to 44.9) |
| Pain at the injection site: Mild | 29.3 (26.4 to 32.3) | 27.7 (24.8 to 30.7) |
| Pain at the injection site: Moderate | 14.8 (12.6 to 17.2) | 14.0 (11.8 to 16.4) |
| Pain at the injection site: Severe | 0 (0.0 to 0.4) | 0 (0.0 to 0.4) |
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Redness: Any | 25.4 (22.6 to 28.3) | 27.2 (24.3 to 30.2) |
| Redness: Mild | 21.1 (18.5 to 23.9) | 23.5 (20.8 to 26.4) |
| Redness: Moderate | 4.3 (3.1 to 5.8) | 3.7 (2.5 to 5.1) |
| Redness: Severe | 0 (0.0 to 0.4) | 0 (0.0 to 0.4) |
| Swelling: Any | 17.1 (14.7 to 19.7) | 17.6 (15.2 to 20.3) |
| Swelling: Mild | 12.5 (10.4 to 14.8) | 13.8 (11.6 to 16.2) |
| Swelling: Moderate | 4.6 (3.3 to 6.2) | 3.8 (2.6 to 5.2) |
| Swelling: Severe | 0 (0.0 to 0.4) | 0.1 (0.0 to 0.6) |
| Pain at the injection site: Any | 38.6 (35.5 to 41.9) | 39.0 (35.8 to 42.2) |
| Pain at the injection site: Mild | 25.7 (22.9 to 28.7) | 25.5 (22.7 to 28.5) |
| Pain at the injection site: Moderate | 12.9 (10.8 to 15.3) | 13.4 (11.3 to 15.8) |
| Pain at the injection site: Severe | 0 (0.0 to 0.4) | 0 (0.0 to 0.4) |
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Redness: Any | 23.5 (20.6 to 26.5) | 26.6 (23.6 to 29.8) |
| Redness: Mild | 19.6 (17.0 to 22.5) | 22.0 (19.2 to 25.0) |
| Redness: Moderate | 3.9 (2.7 to 5.4) | 4.7 (3.3 to 6.3) |
| Redness: Severe | 0 (0.0 to 0.4) | 0 (0.0 to 0.5) |
| Swelling: Any | 14.9 (12.5 to 17.5) | 17.3 (14.8 to 20.1) |
| Swelling: Mild | 10.7 (8.6 to 13.0) | 13.6 (11.3 to 16.2) |
| Swelling: Moderate | 4.2 (3.0 to 5.8) | 3.7 (2.5 to 5.2) |
| Swelling: Severe | 0 (0.0 to 0.4) | 0 (0.0 to 0.5) |
| Pain at the injection site: Any | 35.7 (32.4 to 39.1) | 35.8 (32.5 to 39.2) |
| Pain at the injection site: Mild | 24.1 (21.2 to 27.2) | 27.1 (24.1 to 30.3) |
| Pain at the injection site: Moderate | 11.3 (9.2 to 13.6) | 8.7 (6.9 to 10.9) |
| Pain at the injection site: Severe | 0.4 (0.1 to 1.1) | 0 (0.0 to 0.5) |
Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature greater than or equal to (\>=) 38.0 degrees Celsius (C) and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Fever: >=38.0 degree C | 10.3 (8.5 to 12.3) | 7.5 (5.9 to 9.3) |
| Fever: >=38.0 degree C to 38.4 degree C | 7.3 (5.7 to 9.0) | 6.3 (4.8 to 8.0) |
| Fever: >38.4 degree C to 38.9 degree C | 2.2 (1.4 to 3.3) | 0.9 (0.4 to 1.7) |
| Fever: >38.9 degree C to 40.0 degree C | 0.7 (0.3 to 1.4) | 0.3 (0.1 to 0.9) |
| Fever: >40.0 degree C | 0.1 (0.0 to 0.6) | 0 (0.0 to 0.4) |
| Decreased appetite: Any | 24.4 (21.7 to 27.2) | 23.9 (21.3 to 26.7) |
| Decreased appetite: Mild | 14.5 (12.4 to 16.8) | 16.1 (13.9 to 18.6) |
| Decreased appetite: Moderate | 9.7 (7.9 to 11.7) | 7.5 (5.9 to 9.3) |
| Decreased appetite: Severe | 0.2 (0.0 to 0.7) | 0.3 (0.1 to 0.9) |
| Drowsiness: Any | 67.2 (64.2 to 70.1) | 66.0 (62.9 to 69.0) |
| Drowsiness: Mild | 50.2 (47.0 to 53.3) | 49.3 (46.1 to 52.5) |
| Drowsiness: Moderate | 16.1 (13.9 to 18.5) | 15.6 (13.4 to 18.0) |
| Drowsiness: Severe | 0.9 (0.4 to 1.7) | 1.1 (0.6 to 2.0) |
| Irritability: Any | 70.9 (68.0 to 73.7) | 71.7 (68.7 to 74.5) |
| Irritability: Mild | 23.4 (20.8 to 26.1) | 21.6 (19.0 to 24.3) |
| Irritability: Moderate | 43.0 (39.9 to 46.1) | 46.2 (43.0 to 49.4) |
| Irritability: Severe | 4.5 (3.3 to 6.0) | 3.9 (2.8 to 5.3) |
| Use of antipyretic or pain medication | 35.1 (32.2 to 38.2) | 33.8 (30.8 to 36.8) |
Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>= 38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Fever: >=38.0 degree C | 17.3 (15.0 to 19.9) | 16.3 (14.0 to 18.9) |
| Fever: >=38.0 degree C to 38.4 degree C | 10.9 (8.9 to 13.0) | 10.0 (8.1 to 12.1) |
| Fever: >38.4 degree C to 38.9 degree C | 4.0 (2.9 to 5.5) | 4.2 (3.0 to 5.7) |
| Fever: >38.9 degree C to 40.0 degree C | 2.2 (1.4 to 3.4) | 2.2 (1.3 to 3.3) |
| Fever: >40.0 degree C | 0.2 (0.0 to 0.8) | 0 (0.0 to 0.4) |
| Decreased appetite: Any | 26.4 (23.6 to 29.3) | 23.5 (20.8 to 26.4) |
| Decreased appetite: Mild | 16.4 (14.1 to 18.9) | 15.3 (13.0 to 17.7) |
| Decreased appetite: Moderate | 9.8 (8.0 to 11.9) | 7.7 (6.0 to 9.6) |
| Decreased appetite: Severe | 0.2 (0.0 to 0.8) | 0.5 (0.2 to 1.3) |
| Drowsiness: Any | 54.7 (51.4 to 57.9) | 55.6 (52.4 to 58.9) |
| Drowsiness: Mild | 37.0 (33.9 to 40.2) | 36.9 (33.8 to 40.1) |
| Drowsiness: Moderate | 16.9 (14.6 to 19.5) | 17.9 (15.4 to 20.5) |
| Drowsiness: Severe | 0.7 (0.3 to 1.5) | 0.9 (0.4 to 1.7) |
| Irritability: Any | 71.6 (68.6 to 74.5) | 68.8 (65.7 to 71.8) |
| Irritability: Mild | 22.9 (20.2 to 25.7) | 21.2 (18.6 to 24.0) |
| Irritability: Moderate | 44.7 (41.5 to 47.9) | 43.4 (40.2 to 46.7) |
| Irritability: Severe | 4.0 (2.9 to 5.5) | 4.2 (3.0 to 5.7) |
| Use of antipyretic or pain medication | 40.7 (37.6 to 44.0) | 41.0 (37.8 to 44.3) |
Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>= 38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Fever: >=38.0 degree C | 12.6 (10.5 to 14.9) | 13.7 (11.5 to 16.1) |
| Fever: >=38.0 degree C to 38.4 degree C | 7.7 (6.0 to 9.6) | 7.9 (6.2 to 9.8) |
| Fever: >38.4 degree C to 38.9 degree C | 3.4 (2.3 to 4.8) | 3.9 (2.7 to 5.4) |
| Fever: >38.9 degree C to 40.0 degree C | 1.4 (0.8 to 2.4) | 1.9 (1.1 to 3.0) |
| Fever: >40.0 degree C | 0.1 (0.0 to 0.6) | 0 (0.0 to 0.4) |
| Decreased appetite: Any | 20.6 (18.0 to 23.3) | 22.4 (19.7 to 25.3) |
| Decreased appetite: Mild | 13.5 (11.3 to 15.8) | 13.9 (11.7 to 16.3) |
| Decreased appetite: Moderate | 6.7 (5.1 to 8.5) | 8.2 (6.5 to 10.2) |
| Decreased appetite: Severe | 0.4 (0.1 to 1.1) | 0.3 (0.1 to 1.0) |
| Drowsiness: Any | 44.1 (40.8 to 47.4) | 44.1 (40.8 to 47.4) |
| Drowsiness: Mild | 31.1 (28.1 to 34.2) | 30.1 (27.1 to 33.2) |
| Drowsiness: Moderate | 12.5 (10.4 to 14.8) | 13.1 (11.0 to 15.5) |
| Drowsiness: Severe | 0.5 (0.2 to 1.3) | 0.9 (0.4 to 1.7) |
| Irritability: Any | 64.4 (61.2 to 67.5) | 63.0 (59.8 to 66.2) |
| Irritability: Mild | 25.2 (22.4 to 28.1) | 21.6 (19.0 to 24.5) |
| Irritability: Moderate | 37.5 (34.4 to 40.8) | 39.2 (36.0 to 42.5) |
| Irritability: Severe | 1.8 (1.0 to 2.8) | 2.2 (1.4 to 3.4) |
| Use of antipyretic/pain medication | 36.3 (33.2 to 39.5) | 36.1 (32.9 to 39.3) |
Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>= 38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Fever: >= 38.0 degree C | 14.5 (12.2 to 17.1) | 14.0 (11.7 to 16.6) |
| Fever: >=38.0 degree C to 38.4 degree C | 6.5 (4.9 to 8.4) | 7.7 (6.0 to 9.8) |
| Fever: >38.4 degree C to 38.9 degree C | 5.1 (3.7 to 6.8) | 3.2 (2.1 to 4.6) |
| Fever: >38.9 degree C to 40.0 degree C | 2.7 (1.7 to 4.0) | 2.9 (1.9 to 4.4) |
| Fever: >40.0 degree C | 0.2 (0.0 to 0.9) | 0.1 (0.0 to 0.7) |
| Decreased appetite: Any | 24.8 (21.9 to 27.9) | 25.2 (22.2 to 28.3) |
| Decreased appetite: Mild | 15.9 (13.4 to 18.5) | 16.1 (13.6 to 18.8) |
| Decreased appetite: Moderate | 8.6 (6.8 to 10.7) | 8.3 (6.5 to 10.5) |
| Decreased appetite: Severe | 0.4 (0.1 to 1.1) | 0.7 (0.3 to 1.6) |
| Drowsiness: Any | 39.5 (36.1 to 42.9) | 39.5 (36.1 to 43.0) |
| Drowsiness: Mild | 27.8 (24.8 to 31.0) | 28.2 (25.2 to 31.4) |
| Drowsiness: Moderate | 11.0 (9.0 to 13.4) | 10.7 (8.6 to 13.0) |
| Drowsiness: Severe | 0.6 (0.2 to 1.4) | 0.6 (0.2 to 1.4) |
| Irritability: Any | 61.0 (57.6 to 64.4) | 61.1 (57.7 to 64.5) |
| Irritability: Mild | 23.4 (20.5 to 26.4) | 21.8 (19.0 to 24.8) |
| Irritability: Moderate | 35.0 (31.7 to 38.3) | 37.9 (34.6 to 41.3) |
| Irritability: Severe | 2.7 (1.7 to 4.0) | 1.3 (0.7 to 2.4) |
| Use of antipyretic/pain medication | 37.5 (34.2 to 40.9) | 36.7 (33.4 to 40.1) |
An AE was any untoward medical occurrence in a participants, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3 | 36.6 (33.6 to 39.6) | 39.4 (36.3 to 42.5) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 4 | 15.1 (12.8 to 17.7) | 15.0 (12.6 to 17.6) |
A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalisation or prolongation of existing hospitalisation; was life-threatening; resulted in persistent or significant disability/ incapacity; congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 6 Months Following Dose 4 | 4.5 (3.3 to 6.0) | 3.1 (2.1 to 4.4) |
An NDCMC was defined as a significant disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 6 Months Following Dose 4 | 5.0 (3.7 to 6.5) | 5.9 (4.5 to 7.5) |
Pre-specified levels of serotypes were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per mL (mcg/mL), for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Serotype 1 | 79.8 (76.9 to 82.5) | 88.4 (86.0 to 90.5) |
| Serotype 3 | 52.1 (48.6 to 55.5) | 67.6 (64.2 to 70.8) |
| Serotype 4 | 79.7 (76.8 to 82.4) | 88.2 (85.7 to 90.3) |
| Serotype 5 | 82.5 (79.7 to 85.0) | 86.8 (84.2 to 89.1) |
| Serotype 6A | 93.5 (91.6 to 95.1) | 95.9 (94.3 to 97.2) |
| Serotype 6B | 88.3 (85.9 to 90.4) | 92.4 (90.3 to 94.1) |
| Serotype 7F | 96.6 (95.2 to 97.8) | 97.6 (96.3 to 98.6) |
| Serotype 9V | 81.9 (79.1 to 84.4) | 89.8 (87.5 to 91.8) |
| Serotype 14 | 93.4 (91.5 to 95.0) | 94.1 (92.3 to 95.7) |
| Serotype 18C | 92.6 (90.6 to 94.2) | 93.1 (91.2 to 94.8) |
| Serotype 19A | 97.1 (95.7 to 98.1) | 98.1 (96.9 to 98.9) |
| Serotype 19F | 96.9 (95.5 to 98.0) | 96.6 (95.1 to 97.8) |
| Serotype 23F | 77.9 (74.9 to 80.7) | 85.5 (82.9 to 87.9) |
| Serotype 8 | 96.8 (95.3 to 97.9) | 85.5 (82.9 to 87.9) |
| Serotype 10A | 82.2 (79.5 to 84.8) | 85.5 (82.9 to 87.9) |
| Serotype 11A | 92.7 (90.7 to 94.4) | 85.5 (82.9 to 87.9) |
| Serotype 12F | 67.5 (64.2 to 70.6) | 85.5 (82.9 to 87.9) |
| Serotype 15B | 98.2 (97.0 to 99.0) | 85.5 (82.9 to 87.9) |
| Serotype 22F | 98.3 (97.2 to 99.1) | 85.5 (82.9 to 87.9) |
| Serotype 33F | 86.7 (84.2 to 88.9) | 85.5 (82.9 to 87.9) |
Concentrations of anticapsular IgG for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in all participants at 1 month after Dose 4 using the Luminex assay. Results were expressed as IgG concentrations. GMCs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. Assay result below LLOQ was set to 0.5\*LLOQ. Geometric mean ratios (GMRs) were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CIs (based on Student's t distribution).
| microgram per milliliter (μg/mL) | 20vPnC | 13vPnC |
|---|---|---|
| Serotype 1 | 1.47 (1.37 to 1.57) | 2.12 (1.97 to 2.27) |
| Serotype 3 | 0.56 (0.53 to 0.60) | 0.85 (0.80 to 0.90) |
| Serotype 4 | 3.77 (3.52 to 4.04) | 4.84 (4.50 to 5.22) |
| Serotype 5 | 1.87 (1.74 to 2.00) | 2.51 (2.33 to 2.70) |
| Serotype 6A | 9.01 (8.45 to 9.61) | 11.69 (10.91 to 12.53) |
| Serotype 6B | 4.01 (3.70 to 4.35) | 5.74 (5.27 to 6.24) |
| Serotype 7F | 3.91 (3.70 to 4.35) | 5.18 (4.88 to 5.49) |
| Serotype 9V | 3.44 (3.23 to 3.67) | 4.30 (4.02 to 4.59) |
| Serotype 14 | 5.68 (5.27 to 6.12) | 6.34 (5.88 to 6.83) |
| Serotype 18C | 3.46 (3.24 to 3.70) | 4.69 (4.34 to 5.05) |
| Serotype 19A | 3.53 (3.30 to 3.77) | 4.13 (3.84 to 4.45) |
| Serotype 19F | 5.01 (4.68 to 5.36) | 5.79 (5.36 to 6.25) |
| Serotype 23F | 3.95 (3.63 to 4.31) | 6.18 (5.66 to 6.75) |
| Serotype 8 | 3.97 (3.73 to 4.22) | 0.03 (0.03 to 0.04) |
| Serotype 10A | 6.22 (5.75 to 6.72) | 0.01 (0.01 to 0.01) |
| Serotype 11A | 3.53 (3.31 to 3.78) | 0.02 (0.02 to 0.02) |
| Serotype 12F | 1.85 (1.73 to 1.99) | 0.01 (0.01 to 0.01) |
| Serotype 15B | 12.59 (11.78 to 13.45) | 0.02 (0.02 to 0.03) |
| Serotype 22F | 10.60 (9.92 to 11.33) | 0.00 (0.00 to 0.01) |
| Serotype 33F | 9.31 (8.71 to 9.96) | 0.01 (0.01 to 0.01) |
Concentration of antibody to diphtheria toxoid (predefined level ≥0.1 IU/mL), tetanus toxoid (predefined level ≥0.1 IU/mL), IgG antibodies to pertussis antigens (pertussis toxin, filamentous hemagglutinin and pertactin, each with the predefined level as the 5th percentile observed in the 13vPnC group), hepatitis B antibody (in milli-international units per mL \[mIU/mL\]) (predefined level ≥10 mIU/mL), neutralizing antibody (NA) titers to poliovirus types 1, 2, and 3 (predefined level NA titer ≥1:8), Haemophilus influenzae type b (Hib) (≥0.15 μg/mL) were determined on subsets of sera collected at the immunogenicity time point 1 month after Dose 3. The antibody levels were measured by a validated multiplex Luminex immunoassay. The concomitant immune responses were measured on random subsets.
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Diphtheria | 93.5 (90.5 to 95.8) | 97.8 (95.7 to 99.0) |
| Tetanus | 99.7 (98.5 to 100.0) | 99.4 (98.0 to 99.9) |
| Pertussis (PT) | 94.9 (92.1 to 96.9) | 95.0 (92.3 to 97.0) |
| Pertussis (FHA) | 95.7 (93.1 to 97.5) | 95.0 (92.3 to 97.0) |
| Pertussis (PRN) | 93.8 (90.8 to 96.0) | 95.0 (92.3 to 97.0) |
| hepatitis B surface antigen (HBsAg) | 100.0 (96.9 to 100.0) | 100.0 (97.1 to 100.0) |
| Poliovirus (Type 1) | 100.0 (96.7 to 100.0) | 100.0 (96.9 to 100.0) |
| Poliovirus (Type 2) | 100.0 (96.8 to 100.0) | 99.2 (95.4 to 100.0) |
| Poliovirus (Type 3) | 100.0 (96.8 to 100.0) | 100.0 (97.0 to 100.0) |
| Hib ≥0.15 μg/mL | 100.0 (97.1 to 100.0) | 100.0 (97.1 to 100.0) |
Pneumococcal IgG antibody against each of the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F) was measured using direct binding Luminex assay. Results were expressed as IgG concentrations. GMCs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. Assay result below LLOQ were set to 0.5\*LLOQ.GMRs were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CI (based on Student's t distribution). Assay result below LLOQ were set to 0.5\*LLOQ.GMRs were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CI (based on Student's t distribution).
| μg/mL | 20vPnC | 13vPnC |
|---|---|---|
| Serotype 1 | 0.74 (0.70 to 0.79) | 1.14 (1.06 to 1.22) |
| Serotype 3 | 0.36 (0.33 to 0.38) | 0.51 (0.48 to 0.55) |
| Serotype 4 | 0.75 (0.70 to 0.81) | 1.08 (1.00 to 1.17) |
| Serotype 5 | 0.66 (0.61 to 0.71) | 0.96 (0.88 to 1.04) |
| Serotype 6A | 1.95 (1.81 to 2.10) | 2.69 (2.48 to 2.92) |
| Serotype 6B | 0.61 (0.55 to 0.68) | 1.02 (0.91 to 1.14) |
| Serotype 7F | 1.71 (1.62 to 1.81) | 2.29 (2.16 to 2.43) |
| Serotype 9V | 0.87 (0.81 to 0.93) | 1.21 (1.12 to 1.30) |
| Serotype 14 | 2.16 (2.01 to 2.33) | 2.72 (2.51 to 2.95) |
| Serotype 18C | 1.31 (1.23 to 1.39) | 1.71 (1.59 to 1.84) |
| Serotype 19A | 0.72 (0.67 to 0.76) | 0.91 (0.85 to 0.97) |
| Serotype 19F | 1.59 (1.50 to 1.67) | 2.00 (1.88 to 2.12) |
| Serotype 23F | 0.82 (0.75 to 0.90) | 1.25 (1.14 to 1.37) |
| Serotype 8 | 1.80 (1.70 to 1.91) | 0.02 (0.02 to 0.02) |
| Serotype 10A | 1.21 (1.09 to 1.33) | 0.01 (0.01 to 0.01) |
| Serotype 11A | 1.39 (1.30 to 1.48) | 0.02 (0.01 to 0.02) |
| Serotype 12F | 0.55 (0.50 to 0.60) | 0.01 (0.01 to 0.01) |
| Serotype 15B | 4.40 (4.11 to 4.71) | 0.03 (0.02 to 0.03) |
| Serotype 22F | 3.71 (3.45 to 3.99) | 0.01 (0.00 to 0.01) |
| Serotype 33F | 1.49 (1.36 to 1.64) | 0.02 (0.01 to 0.02) |
Pre-specified levels of serotypes were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per mL (mcg/mL), for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Serotype 1 | 94.3 (92.4 to 95.8) | 97.2 (95.7 to 98.2) |
| Serotype 3 | 73.6 (70.3 to 76.8) | 85.8 (83.1 to 88.2) |
| Serotype 4 | 98.9 (97.9 to 99.5) | 99.1 (98.1 to 99.6) |
| Serotype 5 | 97.9 (96.6 to 98.8) | 97.7 (96.4 to 98.7) |
| Serotype 6A | 99.5 (98.6 to 99.9) | 99.7 (99.0 to 100.0) |
| Serotype 6B | 99.1 (98.1 to 99.6) | 99.5 (98.6 to 99.9) |
| Serotype 7F | 99.5 (98.6 to 99.9) | 99.9 (99.3 to 100.0) |
| Serotype 9V | 98.5 (97.4 to 99.3) | 98.9 (97.9 to 99.5) |
| Serotype 14 | 98.9 (97.9 to 99.5) | 99.5 (98.6 to 99.9) |
| Serotype 18C | 98.9 (97.9 to 99.5) | 99.5 (98.6 to 99.9) |
| Serotype 19A | 99.9 (99.3 to 100.0) | 99.7 (99.0 to 100.0) |
| Serotype 19F | 98.8 (97.7 to 99.5) | 98.9 (97.9 to 99.5) |
| Serotype 23F | 97.2 (95.8 to 98.3) | 98.1 (96.9 to 99.0) |
| Serotype 8 | 99.5 (98.6 to 99.9) | 4.7 (3.3 to 6.5) |
| Serotype 10A | 97.7 (96.4 to 98.7) | 2.0 (1.1 to 3.3) |
| Serotype 11A | 98.8 (97.7 to 99.5) | 4.2 (2.8 to 5.9) |
| Serotype 12F | 95.2 (93.5 to 96.6) | 0.3 (0.0 to 1.0) |
| Serotype 15B | 99.7 (99.0 to 100.0) | 4.6 (3.2 to 6.3) |
| Serotype 22F | 99.6 (98.8 to 99.9) | 1.5 (0.7 to 2.6) |
| Serotype 33F | 99.5 (98.6 to 99.9) | 1.7 (0.9 to 3.0) |
OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomized subsets of participants at 1 month after Dose 3. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. OPA titers were determined in randomized subsets of participants at 1 month after Dose 3.
| Titers | 20vPnC | 13vPnC |
|---|---|---|
| Serotype 1 | 26 (21 to 33) | 34 (27 to 42) |
| Serotype 3 | 51 (43 to 61) | 63 (53 to 76) |
| Serotype 4 | 339 (252 to 455) | 280 (207 to 378) |
| Serotype 5 | 32 (27 to 39) | 39 (32 to 47) |
| Serotype 6A | 910 (763 to 1084) | 936 (757 to 1156) |
| Serotype 6B | 318 (242 to 419) | 516 (409 to 651) |
| Serotype 7F | 1222 (1020 to 1465) | 1149 (926 to 1424) |
| Serotype 9V | 661 (482 to 906) | 594 (421 to 838) |
| Serotype 14 | 415 (323 to 535) | 420 (330 to 535) |
| Serotype 18C | 1153 (910 to 1460) | 996 (754 to 1317) |
| Serotype 19A | 108 (78 to 149) | 109 (79 to 151) |
| Serotype 19F | 84 (67 to 105) | 116 (90 to 149) |
| Serotype 23F | 255 (186 to 350) | 295 (215 to 406) |
| Serotype 8 | 665 (503 to 880) | 18 (17 to 20) |
| Serotype 10A | 2558 (1869 to 3501) | 37 (33 to 42) |
| Serotype 11A | 289 (212 to 395) | 50 (46 to 55) |
| Serotype 12F | 7677 (5952 to 9901) | 28 (24 to 33) |
| Serotype 15B | 1560 (1090 to 2233) | 18 (16 to 22) |
| Serotype 22F | 6797 (5170 to 8936) | 9 (9 to 9) |
| Serotype 33F | 7388 (4803 to 11365) | 198 (177 to 220) |
OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomized subsets of participants at 1 month after Dose 4. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. OPA titers were determined in randomized subsets of participants at 1 month after Dose 4.
| Titers | 20vPnC | 13vPnC |
|---|---|---|
| Serotype 1 | 36 (27 to 48) | 66 (50 to 87) |
| Serotype 3 | 62 (49 to 78) | 102 (86 to 120) |
| Serotype 4 | 621 (435 to 887) | 961 (714 to 1294) |
| Serotype 5 | 55 (45 to 67) | 69 (54 to 87) |
| Serotype 6A | 1384 (1092 to 1753) | 1767 (1329 to 2348) |
| Serotype 6B | 666 (489 to 906) | 1211 (861 to 1703) |
| Serotype 7F | 2022 (1673 to 2444) | 2099 (1741 to 2531) |
| Serotype 9V | 2609 (1913 to 3558) | 3210 (2500 to 4123) |
| Serotype 14 | 667 (523 to 850) | 593 (462 to 761) |
| Serotype 18C | 1973 (1472 to 2643) | 2425 (1914 to 3072) |
| Serotype 19A | 844 (622 to 1145) | 1357 (1007 to 1829) |
| Serotype 19F | 246 (179 to 337) | 373 (272 to 513) |
| Serotype 23F | 827 (554 to 1235) | 1532 (1118 to 2100) |
| Serotype 8 | 1228 (901 to 1673) | 26 (21 to 31) |
| Serotype 10A | 3674 (2746 to 4916) | 57 (44 to 74) |
| Serotype 11A | 2728 (1975 to 3768) | 69 (53 to 89) |
| Serotype 12F | 9320 (7037 to 12343) | 31 (26 to 37) |
| Serotype 15B | 3035 (2138 to 4308) | 23 (17 to 30) |
| Serotype 22F | 11077 (7956 to 15422) | 15 (11 to 20) |
| Serotype 33F | 19216 (13193 to 27990) | 363 (292 to 451) |
GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. The GMFR from 1 month after Dose 3 to before Dose 4 were reported from Dose 3 evaluable immunogenicity participant.
| Fold rise | 20vPnC | 13vPnC |
|---|---|---|
| Serotype 1 | 0.3 (0.3 to 0.3) | 0.3 (0.2 to 0.3) |
| Serotype 3 | 0.2 (0.2 to 0.2) | 0.2 (0.2 to 0.2) |
| Serotype 4 | 0.3 (0.3 to 0.4) | 0.3 (0.3 to 0.3) |
| Serotype 5 | 0.3 (0.3 to 0.3) | 0.3 (0.3 to 0.3) |
| Serotype 6A | 0.3 (0.3 to 0.3) | 0.3 (0.3 to 0.3) |
| Serotype 6B | 0.4 (0.4 to 0.4) | 0.3 (0.3 to 0.3) |
| Serotype 7F | 0.4 (0.4 to 0.6) | 0.4 (0.3 to 0.4) |
| Serotype 9V | 0.3 (0.3 to 0.4) | 0.3 (0.3 to 0.3) |
| Serotype 14 | 0.5 (0.4 to 0.5) | 0.5 (0.4 to 0.5) |
| Serotype 18C | 0.2 (0.2 to 0.2) | 0.2 (0.2 to 0.2) |
| Serotype 19A | 0.2 (0.2 to 0.2) | 0.2 (0.2 to 0.2) |
| Serotype 19F | 0.2 (0.2 to 0.3) | 0.2 (0.2 to 0.2) |
| Serotype 23F | 0.3 (0.3 to 0.3) | 0.3 (0.2 to 0.3) |
| Serotype 8 | 0.2 (0.2 to 0.3) | 1.4 (1.3 to 1.5) |
| Serotype 10A | 0.7 (0.6 to 0.7) | 0.9 (0.9 to 1.0) |
| Serotype 11A | 0.3 (0.2 to 0.3) | 1.1 (1.0 to 1.2) |
| Serotype 12F | 0.3 (0.3 to 0.4) | 1.0 (1.0 to 1.1) |
| Serotype 15B | 0.4 (0.3 to 0.4) | 0.8 (0.7 to 0.8) |
| Serotype 22F | 0.3 (0.3 to 0.4) | 0.8 (0.7 to 0.9) |
| Serotype 33F | 0.7 (0.7 to 0.8) | 0.8 (0.7 to 0.8) |
GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. The GMFR from 1 month before Dose 4 to 1 month after Dose 4 were reported from Dose 4 evaluable immunogenicity participants.
| Fold rise | 20vPnC | 13vPnC |
|---|---|---|
| Serotype 1 | 7.3 (6.9 to 7.8) | 7.1 (6.7 to 7.6) |
| Serotype 3 | 8.5 (7.9 to 9.1) | 9.0 (8.4 to 9.6) |
| Serotype 4 | 15.4 (14.3 to 16.6) | 14.2 (13.1 to 15.3) |
| Serotype 6A | 15.2 (14.3 to 16.2) | 14.5 (13.1 to 15.3) |
| Serotype 6B | 18.0 (16.8 to 19.3) | 17.0 (15.8 to 18.2) |
| Serotype 7F | 6.0 (5.7 to 6.3) | 6.4 (6.0 to 6.8) |
| Serotype 9V | 11.8 (11.1 to 12.6) | 11.2 (10.5 to 11.9) |
| Serotype 14 | 5.9 (5.4 to 6.3) | 5.0 (4.6 to 5.3) |
| Serotype 5 | 8.9 (8.4 to 9.5) | 8.5 (8.0 to 9.0) |
| Serotype 18C | 11.3 (10.6 to 12.0) | 11.4 (10.7 to 12.1) |
| Serotype 19A | 25.6 (23.8 to 27.6) | 25.6 (23.6 to 27.7) |
| Serotype 19F | 13.1 (12.2 to 14.1) | 12.5 (11.6 to 13.5) |
| Serotype 23F | 18.1 (16.8 to 19.5) | 19.2 (17.9 to 20.6) |
| Serotype 8 | 9.1 (8.5 to 9.8) | 1.3 (1.2 to 1.4) |
| Serotype 10A | 8.1 (7.6 to 8.7) | 1.1 (1.0 to 1.1) |
| Serotype 11A | 9.8 (9.1 to 10.6) | 1.1 (1.0 to 1.2) |
| Serotype 12F | 10.0 (9.4 to 10.6) | 1.0 (1.0 to 1.1) |
| Serotype 15B | 8.1 (7.5 to 8.7) | 1.2 (1.2 to 1.3) |
| Serotype 22F | 8.4 (7.9 to 9.1) | 1.2 (1.1 to 1.3) |
| Serotype 33F | 8.8 (8.2 to 9.4) | 1.1 (1.0 to 1.1) |
GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. The GMFR from 1 month after Dose 3 to 1 month after Dose 4 were reported from participants in both Dose 3 and Dose 4 evaluable immunogenicity populations.
| Fold rise | 20vPnC | 13vPnC |
|---|---|---|
| Serotype 1 | 2.0 (1.9 to 2.1) | 1.8 (1.7 to 1.9) |
| Serotype 3 | 1.6 (1.5 to 1.7) | 1.7 (1.6 to 1.8) |
| Serotype 4 | 5.1 (4.8 to 5.5) | 4.4 (4.1 to 4.8) |
| Serotype 5 | 2.9 (2.7 to 3.1) | 2.6 (2.4 to 2.8) |
| Serotype 6A | 4.7 (4.4 to 5.0) | 4.3 (4.0 to 4.6) |
| Serotype 6B | 6.8 (6.2 to 7.4) | 5.5 (5.0 to 6.0) |
| Serotype 7F | 2.3 (2.2 to 2.4) | 2.2 (2.1 to 2.3) |
| Serotype 9V | 4.0 (3.7 to 4.3) | 3.4 (3.2 to 3.7) |
| Serotype 14 | 2.6 (2.4 to 2.9) | 2.2 (2.0 to 2.5) |
| Serotype 18C | 2.7 (2.5 to 2.8) | 2.6 (2.5 to 2.8) |
| Serotype 19A | 4.9 (4.6 to 5.2) | 4.6 (4.2 to 4.9) |
| Serotype 19F | 3.2 (3.0 to 3.4) | 2.9 (2.7 to 3.1) |
| Serotype 23F | 4.9 (4.5 to 5.3) | 4.9 (4.5 to 5.3) |
| Serotype 8 | 2.2 (2.0 to 2.3) | 1.8 (1.6 to 2.0) |
| Serotype 10A | 5.3 (4.9 to 5.8) | 1.0 (0.9 to 1.1) |
| Serotype 11A | 2.6 (2.4 to 2.8) | 1.1 (1.0 to 1.3) |
| Serotype 12F | 3.3 (3.1 to 3.6) | 1.0 (1.0 to 1.1) |
| Serotype 15B | 2.8 (2.6 to 3.0) | 1.0 (0.9 to 1.1) |
| Serotype 22F | 2.9 (2.7 to 3.1) | 1.0 (0.9 to 1.1) |
| Serotype 33F | 6.4 (5.9 to 7.0) | 0.8 (0.8 to 0.9) |
Antibody concentration to the Hib vaccine antigens were determined on sera collected from a randomly selected subset of participants with sufficient sera volumes. Percentage of participants with alternative prespecified Hib antibody (≥1.0 μg/mL) were reported from Dose 3 evaluable immunogenicity participants.
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Percentage of Participants With Alternative Prespecified Hib Antibody Level 1 Month After Dose 3 | 75.0 (66.4 to 82.3) | 72.0 (63.3 to 79.7) |
Antibody concentrations to concomitant vaccine antigen (measles) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.
| AU/mL | 20vPnC | 13vPnC |
|---|---|---|
| Geometric Mean Ratios (GMRs) of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Measles) 1 Month After Dose 4 | 277.74 (243.88 to 316.30) | 215.41 (184.61 to 251.35) |
Antibody concentrations to concomitant vaccine antigen (mumps) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.
| AU/mL | 20vPnC | 13vPnC |
|---|---|---|
| GMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Mumps) 1 Month After Dose 4 | 36.96 (30.82 to 44.33) | 34.19 (28.94 to 40.39) |
Antibody concentrations to concomitant vaccine antigen (rubella) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.
| IU/mL | 20vPnC | 13vPnC |
|---|---|---|
| GMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigens (Rubella) 1 Month After Dose 4 | 49.63 (43.88 to 56.13) | 40.44 (35.19 to 46.48) |
Antibody concentrations to concomitant vaccine antigen (varicella) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.
| mIU/mL | 20vPnC | 13vPnC |
|---|---|---|
| GMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Varicella) 1 Month After Dose 4 | 233.05 (207.25 to 262.06) | 234.78 (208.84 to 263.94) |
Collected over Local reactions (LR) and systemic events (SE) [systematic assessment(SA)]:within 7 days after Dose 1, 2, 3, 4; SAEs: from Dose 1 up to 6 months after Dose 4; other AEs [non-systematic assessment (non-SA)]:from Dose 1 up to 1 month after Dose 3 and from Dose 4 up to 1 month after Dose 4. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 20vPnC | 0/1,001 (0%) | 45/1,001 (4.5%) | 966/1,001 (96.5%) |
| 13vPnC | 0/987 (0%) | 31/987 (3.1%) | 939/987 (95.1%) |
| Event | 20vPnC | 13vPnC |
|---|---|---|
| Respiratory syncytial virus bronchiolitisInfections and infestations | 7/1001 | 3/987 |
| GastroenteritisInfections and infestations | 0/1001 | 5/987 |
| Respiratory syncytial virus infectionInfections and infestations | 5/1001 | 2/987 |
| BronchiolitisInfections and infestations | 4/1001 | 4/987 |
| Escherichia urinary tract infectionInfections and infestations | 0/1001 | 2/987 |
| Febrile convulsionNervous system disorders | 2/1001 | 2/987 |
| PneumoniaInfections and infestations | 2/1001 | 1/987 |
| DehydrationMetabolism and nutrition disorders | 2/1001 | 1/987 |
| Failure to thriveMetabolism and nutrition disorders | 2/1001 | 1/987 |
| Microcytic anaemiaBlood and lymphatic system disorders | 0/1001 | 1/987 |
| Event | 20vPnC | 13vPnC |
|---|---|---|
| Irritability (IRRITABILITY)Psychiatric disorders | 894/1001 | 863/987 |
| Hypersomnia (INCREASED SLEEP)Nervous system disorders | 823/1001 | 798/987 |
| Injection site pain (PAIN)General disorders | 689/1001 | 663/987 |
| Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders | 521/1001 | 492/987 |
| Injection site erythema (REDNESS)General disorders | 498/1001 | 492/987 |
| Injection site swelling (SWELLING)General disorders | 353/1001 | 359/987 |
| Pyrexia (FEVER)General disorders | 322/1001 | 314/987 |
| Upper respiratory tract infectionInfections and infestations | 114/1001 | 112/987 |
| Otitis mediaInfections and infestations | 56/1001 | 50/987 |
Safety population included all participants who received at least 1 dose of 20vPnC or 13vPnC and had safety data assessed after any dose.
| Age, Continuous(Days) | 20vPnC | 13vPnC | Total |
|---|---|---|---|
| Mean | 65.9 ± 7.98 | 65.6 ± 7.12 | 65.8 ± 7.56 |
| Sex: Female, Male(Participants) | 20vPnC | 13vPnC | Total |
|---|---|---|---|
| Female | 483 | 482 | 965 |
| Male | 518 | 505 | 1023 |
| Ethnicity (NIH/OMB)(Participants) | 20vPnC | 13vPnC | Total |
|---|---|---|---|
| Hispanic or Latino | 312 | 293 | 605 |
| Not Hispanic or Latino | 661 | 659 | 1320 |
| Unknown or Not Reported | 28 | 35 | 63 |
| Race (NIH/OMB)(Participants) | 20vPnC | 13vPnC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 3 | 7 |
| Asian | 16 | 16 | 32 |
| Native Hawaiian or Other Pacific Islander | 2 | 2 | 4 |
| Black or African American | 110 | 108 | 218 |
| White | 754 | 742 | 1496 |
| More than one race | 68 | 73 | 141 |
| Unknown or Not Reported | 47 | 43 | 90 |
Showing the first 100 of 110 sites across 2 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from May 2020 to primary completion in Sep 2022, 27 months.
Results were first posted in Dec 2023, 1 year 3 months after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 27 months is above that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine